Trifecta Capital Advisors LLC Makes New $338,000 Investment in 10x Genomics $TXG

Trifecta Capital Advisors LLC bought a new position in 10x Genomics (NASDAQ:TXG) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 29,200 shares of the company’s stock, valued at approximately $338,000.

Several other hedge funds have also added to or reduced their stakes in TXG. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in 10x Genomics by 235.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock worth $62,016,000 after acquiring an additional 4,987,195 shares in the last quarter. Millennium Management LLC boosted its holdings in 10x Genomics by 434.5% in the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock worth $46,946,000 after acquiring an additional 4,371,327 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in 10x Genomics by 3,619.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock worth $10,185,000 after acquiring an additional 1,135,356 shares in the last quarter. Iron Triangle Partners LP bought a new position in shares of 10x Genomics during the first quarter valued at $8,730,000. Finally, ARK Investment Management LLC lifted its holdings in shares of 10x Genomics by 7.5% during the first quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company’s stock valued at $112,143,000 after purchasing an additional 901,656 shares in the last quarter. 84.68% of the stock is owned by institutional investors.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer directly owned 945,892 shares of the company’s stock, valued at $13,043,850.68. The trade was a 0.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,149 shares of company stock valued at $539,865 over the last quarter. 9.39% of the stock is currently owned by company insiders.

10x Genomics Stock Up 4.1%

10x Genomics stock opened at $12.07 on Thursday. The business has a 50-day simple moving average of $13.05 and a two-hundred day simple moving average of $11.03. The company has a market cap of $1.50 billion, a P/E ratio of -17.24 and a beta of 2.05. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $20.83.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. The business had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Research analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TXG. Morgan Stanley reduced their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday, August 12th. UBS Group lifted their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Wall Street Zen upgraded 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. Finally, Piper Sandler began coverage on 10x Genomics in a report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.65.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.